BioVie Inc. (BIVI)
$1.20-9.09%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9M
- Beta
- 0.73
- P/E (TTM)
- -0.38
- Short % float
- 11.08%
- Days to cover
- 2.7
- SI change
- -20.5%
- 1W
- -16.67%
- 1M
- -41.46%
- vs SPY 1W
- -16.53%
- vs SPY 1M
- -43.97%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 1
- GROWTH
- 51
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-75.6%
REV YoY-
ROE-55.0%
EPS YoY-
ROA-154.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.38
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.88
P/FCF-
EV/EBITDA-0.02
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.68
ALTMAN Z-
CURR RATIO3.59
ND/EBITDA-
BETA0.73
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on BIVI?
- LOPJLB’s latest quantitative signal on BioVie Inc. (BIVI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BIVI in?
- BioVie Inc. (BIVI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does BioVie Inc. (BIVI) do?
- BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioV…